| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $3,606,918 | 10 | 36 |
Sells | $139,922 | 18 | 64 |
| Stansky Michael P | director | 2 | $3.01M | 0 | $0 | $3.01M |
| Szela Mary T | CEO and President | 2 | $227,773 | 2 | $79,383 | $148,390 |
| Wahlstrom Mats | director | 1 | $151,800 | 0 | $0 | $151,800 |
| Valle William | director | 1 | $124,997 | 0 | $0 | $124,997 |
| Gordon Gary B. | director | 2 | $64,600 | 0 | $0 | $64,600 |
| Patience David | Chief Financial Officer | 2 | $32,247 | 0 | $0 | $32,247 |
| Devlin Jodi | Chief of Clinical Operations | 0 | $0 | 3 | $13,171 | $-13,171 |
| Cox Bryan F. | Chief of Research | 0 | $0 | 4 | $14,385 | $-14,385 |
| Stevens Jennifer | Chief Regulatory Officer | 0 | $0 | 4 | $15,896 | $-15,896 |
| Marshak Richard | Chief Commercial Officer | 0 | $0 | 5 | $17,086 | $-17,086 |
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates …
Over the last 12 months, insiders at TriSalus Life Sciences, Inc. have bought $3.61M and sold $139,922 worth of TriSalus Life Sciences, Inc. stock.
On average, over the past 5 years, insiders at TriSalus Life Sciences, Inc. have bought $1.48M and sold $126,893 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Stansky Michael P (director) — $3.01M. Szela Mary T (CEO and President) — $227,773. Wahlstrom Mats (director) — $151,800.
The last purchase of 610,000 shares for transaction amount of $1.52M was made by Stansky Michael P (director) on 2026‑05‑15.
| 2026-10-05 | Sale | Cox Bryan F. | Chief of Research | 296 0.0005% | $4.39 | $1,299 | -13.24% | |
| 2026-10-05 | Sale | Marshak Richard | Chief Commercial Officer | 325 0.0006% | $4.39 | $1,427 | -13.24% | |
| 2026-10-05 | Sale | Stevens Jennifer | Chief Regulatory Officer | 316 0.0005% | $4.39 | $1,387 | -13.24% | |
| 2026-05-15 | Sale | Marshak Richard | Chief Commercial Officer | 543 0.0014% | $2.67 | $1,450 | +59.70% | |
| 2026-05-15 | Stansky Michael P | director | 610,000 1.501% | $2.50 | $1.52M | +59.70% | ||
| 2026-05-15 | Szela Mary T | CEO and President | 39,682 0.1012% | $2.59 | $102,776 | +59.70% | ||
| 2026-05-15 | Patience David | Chief Financial Officer | 7,100 0.017% | $2.43 | $17,253 | +59.70% | ||
| 2026-05-15 | Wahlstrom Mats | director | 60,000 0.1494% | $2.53 | $151,800 | +59.70% | ||
| 2026-05-15 | Gordon Gary B. | director | 10,000 0.0242% | $2.46 | $24,600 | +59.70% | ||
| 2026-03-17 | Sale | Szela Mary T | CEO and President | 15,944 0.0403% | $3.85 | $61,384 | +6.47% | |
| 2026-03-16 | Sale | Cox Bryan F. | Chief of Research | 579 0.0015% | $4.12 | $2,385 | +3.64% | |
| 2026-03-16 | Sale | Stevens Jennifer | Chief Regulatory Officer | 774 0.002% | $4.12 | $3,189 | +3.64% | |
| 2026-03-16 | Sale | Marshak Richard | Chief Commercial Officer | 419 0.0011% | $4.12 | $1,726 | +3.64% | |
| 2026-03-16 | Sale | Devlin Jodi | Chief of Clinical Operations | 273 0.0007% | $4.12 | $1,125 | +3.64% | |
| 2026-03-12 | Sale | Cox Bryan F. | Chief of Research | 1,467 0.0039% | $4.09 | $6,000 | +4.15% | |
| 2026-03-12 | Sale | Stevens Jennifer | Chief Regulatory Officer | 1,552 0.0041% | $4.09 | $6,348 | +4.15% | |
| 2026-03-12 | Sale | Marshak Richard | Chief Commercial Officer | 1,589 0.0042% | $4.09 | $6,499 | +4.15% | |
| 2026-03-12 | Sale | Devlin Jodi | Chief of Clinical Operations | 1,772 0.0047% | $4.09 | $7,247 | +4.15% | |
| 2026-03-11 | Sale | Szela Mary T | CEO and President | 4,358 0.0114% | $4.13 | $17,999 | +2.52% | |
| 2026-03-11 | Sale | Cox Bryan F. | Chief of Research | 1,138 0.003% | $4.13 | $4,700 | +2.52% |
| Stansky Michael P | director | 1240722 2.015% | $4.32M | 2 | 0 | |
| Szela Mary T | CEO and President | 1065215 1.73% | $3.71M | 9 | 2 | +2.53% |
| Patience David | Chief Financial Officer | 275757 0.4478% | $959,634.36 | 2 | 0 | |
| Wahlstrom Mats | director | 147555 0.2396% | $513,491.40 | 4 | 0 | +15.83% |
| Gordon Gary B. | director | 72510 0.1178% | $252,334.80 | 2 | 0 | |
| Valle William | director | 30487 0.0495% | $106,094.76 | 1 | 0 | |
| Frankenius Equity AB | 10 percent owner | 6230748 10.119% | $21.68M | 1 | 0 | +34.12% |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. | 197732 0.3211% | $688,107.36 | 2 | 0 | +1.18% |
| Young James Emmett | Chief Financial Officer | 30000 0.0487% | $104,400.00 | 2 | 0 | <0.0001% |
$9,837,727 | 35 | 7.68% | $94.71M | |
$1,105,104 | 34 | -11.40% | $311.25M | |
$20,867,362 | 27 | -3.90% | $467.11M | |
$58,749,198 | 24 | 16.21% | $100.45M | |
TriSalus Life Sciences, Inc. (TLSI) | $842,771 | 15 | 6.44% | $214.28M |
| Increased Positions | 40 | +70.18% | 2M | +23.7% |
| Decreased Positions | 22 | -38.6% | 478,418 | -4.93% |
| New Positions | 14 | New | 337,360 | New |
| Sold Out Positions | 9 | Sold Out | 123,062 | Sold Out |
| Total Postitions | 75 | +31.58% | 12M | +18.77% |
| Nantahala Capital Management, Llc | $12,445.00 | 4.08% | 2.04M | +40,245 | +2.01% | 2025-09-30 |
| Awm Investment Company, Inc. | $7,625.00 | 2.5% | 1.25M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $7,073.00 | 2.32% | 1.16M | +345,186 | +42.39% | 2025-09-30 |
| Gilder Gagnon Howe & Co Llc | $6,387.00 | 2.09% | 1.05M | -45,916 | -4.2% | 2025-09-30 |
| Blackrock, Inc. | $4,806.00 | 1.58% | 787,864 | +166,175 | +26.73% | 2025-09-30 |
| Wealthcare Advisory Partners Llc | $3,927.00 | 1.29% | 643,740 | 0 | 0% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $3,401.00 | 1.12% | 557,500 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $3,382.00 | 1.11% | 554,455 | +99,404 | +21.84% | 2025-09-30 |
| State Street Corp | $1,175.00 | 0.39% | 192,633 | +77,036 | +66.64% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,154.00 | 0.38% | 189,180 | +274 | +0.14% | 2025-09-30 |